Inhibikase Therapeutics Inc. (IKT)
Market Closed
16 Oct, 08:00 PM
NASDAQ (CM) NASDAQ (CM) Primary 
XMUN $
1. 65
-0.18
-9.8361%
$
260.11M Market Cap
- P/E Ratio
- Div Yield
917,213 Volume
-1.77 Eps
$ 1.83
Previous Close 
Want to track IKT and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Inhibikase Therapeutics Inc. (IKT) Statistics
Valuation metrics
Market Cap 260.11M
Enterprise value 228.9M
Trailing P/E (ttm) -4.15
Forward P/E -
PEG ratio -0.03
Price/Sales (ttm) -
Price/Book (mrq) 2.24
Enterprise Value/Revenue -
Enterprise Value/EBITDA -3.67
Overview
Shares outstanding -
Float -
Shares short -
% Held by insiders -
% Held by institutions -
Average volume (10 days) 435K
Average volume (90 days) 669.07K
Price summary
52-Week low 1.33
52-Week high 2.61
Beta -
50-Day moving average 2.29
200-Day moving average 1.93
Dividends and splits
Forward annual dividend rate -
Forward annual dividend yield -
Trailing annual dividend rate -
Trailing annual dividend yield -
5-Year annual dividend yield -
Payout ratio -
Dividend Date -
Ex-Dividend Date -
Last split factor 1:6
Last split Date 30 Jun 2023
Financials
Fiscal year
Fiscal year ends -
Most recent quarter (mrq) -
Profitability
Profit margin -
Operating margin -
Operational effectiveness
Return on assets -0.37%
Return on equity -0.43%
Income Statement
Revenue (ttm) -
Revenue per share (ttm) -
Quarterly revenue growth (yoy) -
Gross profit (ttm) -
EBITDA -
Net income to common (ttm) -
Diluted EPS (ttm) -0.35
Quarterly earnings growth (yoy) -
Balance Sheet
Total cash (mrq) -
Total cash per share (mrq) 0.91
Total debt (mrq) -
Total Debt/Equity (mrq) -
Current ratio (mrq) 15.82%
Book value per share (mrq) 0.88
Cash Flow
Cash flow statement -
Levered free cash flow (LFCF) -
2026 © Marketlog. All Rights Reserved.
